$655.96+$4.05 (+0.62%)as of market close, Jul 24, 2026
REGN — Regeneron Pharmaceuticals Inc. stock price, chart and key statistics
Key stats
Price data
- Price
- $655.96
- Change YTD
- -15.50%
- Next earnings
- Jul 30, 2026 · Before open
- Market cap
- 70.6B
- Enterprise value
- 69.7B
- Shares outstanding
- 107.7M
- 52W low
- $541.00
- 52W high
- $821.11
- From 52W high
- -20.11%
- From 52W low
- +21.25%
- 52W range
- 41%
- Beta
- 0.24
Volume
- Rel volume
- 1.03×
- 30D volume
- 895.7K
- 30D $ vol
- 570.7M
Fundamentals
- Sales (ttm)
- 14.9B
- Sales/share
- $138.53
- EPS (ttm)
- $41.07
- FCF (ttm)
- 4.1B
- FCF/share
- $38.19
- Book value/share
- $291.77
- Net margin
- 29.65%
- ROE
- 14.08%
- ROA
- 10.82%
- Debt / equity
- 0.06×
- Current ratio
- 3.57
Growth (CAGR, ttm) · 10Y
- Sales
- +12.90%
- Net income
- +19.56%
- FCF
- +17.65%
- Shares
- -0.59%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +20.36%
- Sales/share
- +13.57%
- FCF/share
- +18.35%
- Book value/share
- +24.37%
- Price
- +5.30%
- Total return
- +5.38%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 16.0×
- Fwd P/E
- 12.1×
- P/S (ttm)
- 4.7×
- P/B (mrq)
- 2.2×
- P/FCF (ttm)
- 17.2×
- EV/EBITDA (fy)
- 16.9×
- EV/Sales (ttm)
- 4.7×
- FCF yield (ttm)
- 5.82%
- Dividend yield (fwd)
- 0.57%
- Dividend/share (fwd)
- $3.76
- Buyback yield (ttm)
- 3.47%
- Shareholder yield (ttm)
- 4.00%
Vs own 10Y history
- P/E
- 29th
- P/S
- 12th
- P/B
- 7th
- P/FCF
- 20th
Bar = where today's multiple sits in REGN's own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance
1D
+0.62%
1W
-3.06%
1M
+5.22%
3M
-14.37%
YTD
-15.50%
1Y
+14.60%
5Y
+12.47%
Financial statements
Open full REGN financials →Related Healthcare
1MRegeneron Pharmaceuticals Inc. (REGN) trades at $655.96 with a live price and an interactive chart covering 35+ years of daily price history, plus key valuation metrics. ChartRow also publishes REGN's financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full REGN financial statements →